Novartis AG vs ZIM Integrated Shipping Services Ltd — how do they compare? Novartis AG trades at $152.6 (market cap $295.37B), while ZIM Integrated Shipping Services Ltd trades at $25.04 (market cap $2.96B). The key difference: Novartis AG is far larger — about 99.8× ZIM Integrated Shipping Services Ltd's market cap, and ZIM Integrated Shipping Services Ltd pays the higher dividend (20.16%). Which is the better fit depends on your goals.
| NVS | ZIM | |
|---|---|---|
Market Cap | $295.37B | $2.96B |
Sector | Health | Industrials |
52-Week High | $168.62 | $29.27 |
52-Week Low | $119.31 | $12.44 |
Enterprise Value | $336.69B | $6.81B |
Dividend Yield | 3.07% | 20.16% |
Signals from Pluang's Aura AI — not financial advice
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
ZIM Integrated Shipping Services trades at $24.91, down 1.19% for the day, with a bearish technical outlook and mixed fundamental picture. The stock shows attractive valuation metrics including P/S of 0.47 and P/B of 0.77, but faces profitability challenges with a 1.56% net margin. Recent Q1 2026 earnings missed expectations, while Q2 results are anticipated amid merger uncertainty with Hapag-Lloyd.
The outlook remains cautious with analyst consensus evenly split between Hold and Sell ratings and a $16.75 price target well below current levels. Key risks include regulatory hurdles for the proposed merger, declining revenue projections, and volatile shipping rates. The company's strong cash position provides some downside protection, but near-term headwinds outweigh growth catalysts.
Trailing returns across standard periods
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →